Loading
Life sciences · Journal article
Bioscientia Medicina Journal of Biomedicine and Translational Research · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Luminal B HER2-negative breast cancer responds only modestly to neoadjuvant chemotherapy (NAC), and the receptor profile of its residual tumor may differ from that of the original biopsy. Objective: To test whether subtype conversion after NAC is associated with pathological response. Methods: This retrospective cross-sectional study included 49 consecutive women with stage IIIA–IIIB Luminal B HER2-negative cancer who received doxorubicin–cyclophosphamide or docetaxel–cyclophosphamide before mastectomy at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia (2024–2025). Conversion meant any change in immunohistochemical surrogate subtype between core biopsy and mastectomy. The outcomes were the Miller–Payne grade (primary) and the Residual Cancer Burden (RCB) class. Exact tests, proportional-odds and Firth logistic regression, and Holm correction were applied. Results: Conversion occurred in 14 patients (28.6%; 95% CI 17.8–42.4), most often to Luminal B HER2-positive. Converted tumors had lower Miller–Payne grades (exact p = 0.027). None reached grade 4–5 (0/14 vs 9/35; p = 0.045). The adjusted cumulative odds ratio was 0.27 (95% CI 0.08–0.91). RCB-III was more frequent after conversion (78.6% vs 31.4%; adjusted OR 6.54, 95% CI 1.69–31.63). The association between conversion and the RCB class was the only one surviving Holm correction (p = 0.019), and the RCB-III association depended largely on eight HER2 gains defined by immunohistochemistry alone. Conclusion: More than one in four Luminal B HER2-negative tumors changed surrogate subtype after NAC. Conversion, mostly HER2 gain, marked heavier residual disease. Before adjuvant therapy is chosen, receptors should be re-tested on residual tumor, with in situ hybridization to confirm HER2.